We are a reliable, self-sustaining computational chemistry company. We offer our software and expertise to both smaller biotech companies and big pharma, either as a CRO or as licensed software, for use in the preclinical stages of drug discovery.
Are you a biotech kicking off a new project, looking for rational computer-aided drug design (CADD) to accelerate your hit discovery? We use our own software tools and a structure-based approach to identify novel small molecules targeting any protein family.
Do you need diverse comp. chem. expertise, but only employ a small in-house team, or no team at all? When you hire us as a CRO, we source our entire team’s experience in areas including structure-based design, chemoinformatics, quantum mechanics, and molecular dynamics.
Do you struggle with third-party software, hidden license requirements, and missing features? We develop our own software for most applications, precluding the need to sign other agreements or to procure other tools. We can also adjust and enhance our procedures to accommodate different project workflows. Our software works on PC, Linux, and Mac and we will run demos and workshops.
Are you looking for a long-term partner with flexibility in how you collaborate? We construct our agreements on FFS or FTE bases and generally do not retain IP on your projects. We conduct feasibility studies before spending time and money on projects that are unlikely to be successful. We will provide reports, communicate regularly, and return any generated data.
James Talton, CEO of Alchem Laboratories says, “We reviewed multiple software packages and MFI ranked in the top 10. Adding in their service and expertise made them an excellent partner on our DOD project. We’re excited by the results thus far and will absolutely continue working with their team in the future.
Contact us to start your project today! Don't forget to follow us on Twitter @MolForecaster!
Find our testimonials and references on our website!
Are you a biotech kicking off a new project, looking for rational computer-aided drug design (CADD) to accelerate your hit discovery? We use our own software tools and a structure-based approach to identify novel small molecules targeting any protein family.
Do you need diverse comp. chem. expertise, but only employ a small in-house team, or no team at all? When you hire us as a CRO, we source our entire team’s experience in areas including structure-based design, chemoinformatics, quantum mechanics, and molecular dynamics.
Do you struggle with third-party software, hidden license requirements, and missing features? We develop our own software for most applications, precluding the need to sign other agreements or to procure other tools. We can also adjust and enhance our procedures to accommodate different project workflows. Our software works on PC, Linux, and Mac and we will run demos and workshops.
Are you looking for a long-term partner with flexibility in how you collaborate? We construct our agreements on FFS or FTE bases and generally do not retain IP on your projects. We conduct feasibility studies before spending time and money on projects that are unlikely to be successful. We will provide reports, communicate regularly, and return any generated data.
James Talton, CEO of Alchem Laboratories says, “We reviewed multiple software packages and MFI ranked in the top 10. Adding in their service and expertise made them an excellent partner on our DOD project. We’re excited by the results thus far and will absolutely continue working with their team in the future.
Contact us to start your project today! Don't forget to follow us on Twitter @MolForecaster!
Find our testimonials and references on our website!
Location: Canada, Montreal (06), Montreal
Employees: 1-10
Founded date: 2010
Investors 1
| Date | Name | Website |
| 31.05.2021 | Aligo Inno... | technology... |
Mentions in press and media 1
| Date | Title | Description |
| 28.09.2021 | adMare’s Accelerate Quebec Company, Molecular Forecaster, Continues Quest to Fast Track Drug Discovery with Two New Public-Private Partnerships | The company and its partners have secured CAD$1 million to apply and improve MFI’s virtual drug-design software in support of preclinical research targeting antibiotic-resistant bacteria and non-alcoholic fatty liver disease Montreal, Quebe... |